SGHT · Sight Sciences

The thesis

Sight Sciences' TearCare dry-eye treatment is becoming a second revenue line beside its OMNI glaucoma devices. That gives the shares a slightly better than even chance of beating the S&P 500 over the next three months. The case is tested by new Medicare contractor and insurer coverage for TearCare and then by the fourth-quarter report. Management's 2 December 2026 conference appearance is the next public update.

The 4 November 2026 report showed dry-eye revenue of $3.9 million, up 45% from the second quarter. The company also raised 2026 revenue guidance to $92–93 million. At the Stifel Healthcare Conference on 11 November 2026, management said the guidance-implied flat fourth quarter for TearCare reflects conservative planning, according to Investing.com's account of the session. It also said further coverage or fee schedules are "within quarters." On 12 November 2026, UBS kept its Buy rating and raised its target to $13.50 from $8, according to MarketBeat, which relayed a Benzinga report.

The rating sits one step above even because revenue, guidance, the new Medicare supply code and three raised or new analyst targets all point the same way. Fourth-quarter dry-eye revenue and the timing of payer decisions are still open. The market has already priced in much of the third-quarter improvement. The shares closed at $10.99 on 12 November 2026, up 35.0% over three months and above MarketBeat's $10.31 consensus target from eight analysts (12 November 2026).

Bullish and bearish views on Sight Sciences, Inc.

The bull case on Sight Sciences, Inc. (SGHT), in brief: dry-eye growth came from more accounts. The bear case: guidance implies a flat dry-eye quarter.

Bull case

• Dry-eye growth came from more accounts. Active TearCare customers reached 222 in the third quarter, against 176 in the second, 96 in the first and 50 a year earlier (company release, 4 November 2026; Stifel session, 11 November 2026). TearCare SmartLids sold reached 4,581, against 271 a year earlier.
• Most TearCare volume is already reimbursed. On 11 November 2026, management said most current TearCare business is covered and paid (Investing.com). The coverage comes from Medicare contractors First Coast and Novitas, which cover about 15 million lives. Procedures are running at about 20,000 a year, or about 1% to 2% of patients with moderate-to-severe meibomian gland dysfunction in those regions.
• Medicare set a supply price for SmartLids. The Centers for Medicare & Medicaid Services (CMS) created supply code SD397 at $1,000, effective 1 January 2027, in its 2027 Physician Fee Schedule final rule (company release, 5 November 2026). On 11 November 2026, management called it an important reference point for talks with payers.
• Guidance rose for the third time in 2026. The revenue range went to $83–89 million on 6 May 2026, $88–92 million on 5 August 2026 and $92–93 million on 4 November 2026. The latest range sits above the $90.32 million analyst estimate (Benzinga, 4 November 2026).
• Analysts raised targets after the report. UBS raised its target to $13.50 from $8 on 12 November 2026, and Piper Sandler raised its target to $12 from $9 on 5 November 2026 (MarketBeat; Benzinga). H.C. Wainwright started coverage at Buy with a $14 target on 15 October 2026.
• Margins improved and cash use fell. Dry-eye gross margin was 79.0% in the third quarter, against 37.8% a year earlier (company release, 4 November 2026). Cash used in the quarter was $2.4 million, against $9.1 million a year earlier, which left $77.4 million at 30 September 2026.

Bear case

• Guidance implies a flat dry-eye quarter. On the 4 November 2026 call, Piper Sandler's Kyle Winborne estimated that about $12 million of full-year dry-eye revenue implies about 6% growth in the fourth quarter from the third, after 45% in the third. On 11 November 2026, management said this reflected conservative planning but did not change the guidance.
• Payer timing is outside the company's control. Medicare contractors still price procedure code CPT 0563T one by one, and SD397 sets no national rate or separate SmartLids payment (company release, 5 November 2026). On 11 November 2026, management's only timeline for new coverage was "within quarters."
• Glaucoma, the larger business, grew slowly. Interventional Glaucoma produced $21.0 million of the $24.9 million third-quarter revenue, up 7% (company release, 4 November 2026). The Stifel moderator noted on 11 November 2026 that the midpoint of glaucoma guidance implies a fourth-quarter decline from the third. Management expects only a modest fourth-quarter contribution from OMNI Ultra.
• Losses continue. The company lost $6.8 million in the third quarter and carried $40.0 million of debt at 30 September 2026 (company release, 4 November 2026). MarketBeat's consensus 2026 loss is $0.48 a share (12 November 2026), and H.C. Wainwright models a $0.20 loss for 2027 (9 November 2026).
• The shares trade above the consensus target. The $10.99 close on 12 November 2026 sits above MarketBeat's $10.31 consensus target, which rests on five Buy, two Hold and one Sell rating (12 November 2026). Only the UBS, Piper Sandler and H.C. Wainwright targets are higher.
• Executives sold in early October. CEO Paul Badawi sold 29,653 shares and CTO David Badawi sold 7,797 shares at $9.05 on 1 October 2026. On 2 October 2026, COO Alison Bauerlein sold 25,260 shares, CFO James Rodberg 7,208 and EVP Brenton Taylor 2,988, all at $8.85. All five sales were made under Rule 10b5-1 trading plans (SEC Form 4 filings, 5 October 2026).

Price setup

The shares closed at $10.99 on 12 November 2026, 5.3% below the 52-week intraday high of $11.60 reached that same session. They are up 35.0% over three months from the $8.14 close of 14 August 2026. The 52-week closing low was $3.45 on 10 April 2026.

On 12 November 2026, the 50-day moving average stood at $8.92 and the 200-day at $6.16 (adjusted daily closes), so the shares trade well above both. The rally after the report began at the $9.76 close on 5 November 2026, the first session after the results, and continued to $10.08 on 6 November 2026 and $11.01 on 9 November 2026. Since then the shares have held between $10.75 and $10.99 at the close. A fall back to the 50-day average would put the shares near the $8.85–$9.05 prices of the executives' October sales.

MarketBeat put the market value at $625.54 million on 12 November 2026, with insiders owning 30.40% and institutions 55.51%. With a modest freely traded share count, moves can be sharp in both directions.

Catalysts ahead

• 2 December 2026: Fireside chat at the Piper Sandler 38th Annual Healthcare Conference, 3:00 pm ET. It gives a further read on OMNI Ultra uptake and on whether any new Medicare contractor or commercial insurer has moved toward TearCare coverage.
• 1 January 2027: CMS supply code SD397 for TearCare SmartLids takes effect at $1,000. It gives Medicare contractors and insurers a published supply price when they set procedure payment, though it sets no national rate.
• ~5 March 2027 (est.): Fourth-quarter and full-year 2026 results. It shows whether dry-eye revenue grows beyond $3.9 million, whether revenue meets the $92–93 million range, how OMNI Ultra sold, and what 2027 guidance looks like.

What would change the view

A daily close below $8.70, under the 50-day moving average and the $8.85–$9.05 prices of executives' early-October sales, which would undo the post-report rally. Fourth-quarter dry-eye revenue below the third quarter's $3.9 million, or 2026 revenue below the $92 million low end of guidance, would also show the case failing.

The risks this note tracks, each with what would confirm it:

• Dry-eye growth stalls, as the guidance-implied flat fourth quarter suggests. Confirmed by: fourth-quarter dry-eye revenue below $3.9 million, or full-year dry-eye revenue short of about $12 million.
• Medicare contractors and insurers take longer than expected to pay for TearCare, despite the new supply code. Confirmed by: no new contractor fee schedule or major insurer coverage decision beyond First Coast and Novitas by the fourth-quarter report.
• Glaucoma revenue stalls as OMNI Ultra replaces older models or competing procedures take share. Confirmed by: fourth-quarter Interventional Glaucoma revenue under the third quarter's $21.0 million.
• Losses and spending rise again, raising the prospect of new share issuance. Confirmed by: an equity offering filed with the SEC, or 2026 adjusted operating expenses above the $92–94 million range.
• The shares trade above the $10.31 consensus target, leaving little room if more analysts do not raise their targets. Confirmed by: analyst target cuts or downgrades after the 4 November 2026 report, or further Form 4 sales by executives.
• Alcon wins its appeal and the Hydrus damages and royalty are reduced or overturned. Confirmed by: an appeals court ruling vacating or cutting the 27 March 2026 judgment.

What it trades with

Sight Sciences trades mainly on its own news. Benzinga reported that the shares jumped on 15 October 2026, after H.C. Wainwright started coverage. The shares then rose from $9.76 on 5 November 2026 to $11.01 on 9 November 2026, across the report and the 5 November 2026 supply-code release. MarketBeat lists a beta of 2.44 (12 November 2026), so the shares have moved more than the market in both directions. The closest business link is in glaucoma surgery devices, where Alcon's Hydrus Microstent competes with OMNI and is the subject of the patent judgment. On 11 November 2026, Sight Sciences named LipiFlow and iLux as its dry-eye competitors.